Clinical binding properties, internalization kinetics, and clinicopathologic activity of brentuximab vedotin: an antibody-drug conjugate for CD30-positive lymphoid neoplasms

Clin Lymphoma Myeloma Leuk. 2012 Aug;12(4):280-3. doi: 10.1016/j.clml.2012.01.012. Epub 2012 Apr 26.

Authors

Jonathan R Fromm¹, Julie A McEarchern, Dana Kennedy, Anju Thomas, Andrei R Shustov, Ajay K Gopal

Affiliation

¹ Department of Laboratory Medicine, University of Washington, Seattle, Washington 98195, USA. [email protected]

PMID: 22542449
DOI: 10.1016/j.clml.2012.01.012

No abstract available

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Antineoplastic Agents / adverse effects
Antineoplastic Agents / pharmacokinetics
Antineoplastic Agents / therapeutic use
Brentuximab Vedotin
Humans
Immunoconjugates / adverse effects
Immunoconjugates / pharmacokinetics*
Immunoconjugates / therapeutic use*
Ki-1 Antigen / metabolism*
Lymphoma, Large-Cell, Anaplastic / drug therapy*
Lymphoma, Large-Cell, Anaplastic / metabolism*
Lymphoma, Large-Cell, Anaplastic / pathology
Male
Prognosis

Substances

Antineoplastic Agents
Immunoconjugates
Ki-1 Antigen
Brentuximab Vedotin